{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:28:34Z","timestamp":1787138914715,"version":"build-2736575974"},"reference-count":18,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,8,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blinatumomab, a bispecific CD19 \u00d7 CD3 antibody is effective for the treatment of B\u2010cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (FDA) recommends preemptive hospitalization for the initiation of cycle 1 (C1) and cycle 2 (C2). The necessity of this approach is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The authors conducted a retrospective cohort study among all patients treated with blinatumomab between 2012 and 2025 at two academic cancer centers: Memorial Sloan Kettering Cancer Center (MSK) and Dana\u2010Farber Cancer Institute (DFCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For C1, only nine of 308 (3%) patients initiated outpatient (OP) treatment. A total of 184 of 308 (60%) initiated C2: At DFCI, 10 of 83 (12%) initiated C2 OP and at MSK, and 74 of 101 (88%) initiated C2 OP. Demographic and clinical characteristics were similar between patients initiating C2 inpatient versus OP. No patients who initiated C2 (0 of 184) had Gr3+ CRS (across all cycles) and only two (1%) had Gr3+ ICANS; both were inpatient for C2. Of 84 patients treated without preemptive hospitalization for C2, 16 of 84 (19%) required hospitalization at some point during the cycle, largely for infections (50%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OP administration of C2 of blinatumomab can be administered safely with no unexpected, severe, or life\u2010threatening toxicities. The ability to safely manage treatment without preemptive hospitalization may support the patient experience and limit costs of care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70566","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:52:42Z","timestamp":1787061162000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blinatumomab administration in the outpatient setting: Safety and health care utilization"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-8006","authenticated-orcid":false,"given":"Yannis K.","family":"Valtis","sequence":"first","affiliation":[{"name":"Department of Medicine Cellular Therapy Service Memorial Sloan Kettering Cancer Center  New York New York USA"},{"name":"Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin F.","family":"Frost","sequence":"additional","affiliation":[{"name":"Department of Medicine Brigham and Women\u2019s Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nemirovsky","sequence":"additional","affiliation":[{"name":"Department of Medicine Biostatistics Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[{"name":"Department of Medicine Biostatistics Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo\u2010Kai","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-2773","authenticated-orcid":false,"given":"Meira Yisraeli","family":"Salman","sequence":"additional","affiliation":[{"name":"Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-2071","authenticated-orcid":false,"given":"Leora","family":"Boussi","sequence":"additional","affiliation":[{"name":"Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1545-1253","authenticated-orcid":false,"given":"Natalia Tijaro","family":"Ovalle","sequence":"additional","affiliation":[{"name":"Department of Medicine Adult Bone Marrow Transplant Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Baxter","sequence":"additional","affiliation":[{"name":"Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2452-9051","authenticated-orcid":false,"given":"Ann","family":"Mercurio","sequence":"additional","affiliation":[{"name":"Department of Medicine Mount Sinai Morningside\/West  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Geyer","sequence":"additional","affiliation":[{"name":"Department of Medicine Cellular Therapy Service Memorial Sloan Kettering Cancer Center  New York New York USA"},{"name":"Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Schrag","sequence":"additional","affiliation":[{"name":"Department of Medicine Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar H.","family":"Kelkar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine Cellular Therapy Service Memorial Sloan Kettering Cancer Center  New York New York USA"},{"name":"Department of Medicine Leukemia Service Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK\u201025\u2010473148"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)71170\u20102"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201008\u2010798322"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_2_9_8_1","unstructured":"Food and Drug Administration.Blincyto Label. Accessed January 1 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125557Orig1s028Correctedlbl.pdf"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u2010NB2018\u2010136"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000307"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013239"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19090"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.46989\/001c.115793"},{"key":"e_1_2_9_14_1","unstructured":"Food and Drug Administration.Columvi (Label). Accessed January 20 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761309s000lbl.pdf"},{"key":"e_1_2_9_15_1","unstructured":"Food and Drug Administration.Epkinly (Label). Accessed January 20 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761324s000lbl.pdf"},{"key":"e_1_2_9_16_1","unstructured":"Food and Drug Administration.Lunsumio (Label). Accessed January 20 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761263s000lbl.pdf"},{"key":"e_1_2_9_17_1","unstructured":"Food and Drug Administration.Tecvayli (Label). Accessed January 20 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf"},{"key":"e_1_2_9_18_1","unstructured":"Food and Drug Administration.Elrexfio (Label). Accessed January 20 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345Orig1s000lbl.pdf"},{"key":"e_1_2_9_19_1","unstructured":"Food and Drug Administration.Talvey (Label). Accessed January 20 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70566","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:12:14Z","timestamp":1787137934000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":18,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,15]]}},"alternative-id":["10.1002\/cncr.70566"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70566","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"2026-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70566"}}